InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Pharmaxis Earns A$15 Million Milestone Payment 11 Jan 2018 8:32AM $0.265 $0.027 fallen by 89.81%
- New Australian PBS Listing for Brocnhitol 2 Jan 2018 8:28AM $0.255 $0.027 fallen by 89.41%
- Pharmaxis Acquires Control, Increases Stake in LOXL2 Program 14 Dec 2017 8:27AM $0.260 $0.027 fallen by 89.62%
- Appendix 3B - Grant of Employee Peformance Rights 14 Nov 2017 8:37AM $0.260 $0.027 fallen by 89.62%
- Change of Director's Interest Notice - G Phillips 14 Nov 2017 8:37AM $0.260 $0.027 fallen by 89.62%
- Results of Meeting 14 Nov 2017 8:37AM $0.260 $0.027 fallen by 89.62%
- CEO Presentation to 2017 AGM 13 Nov 2017 1:29PM $0.265 $0.027 fallen by 89.81%
- Chairman's Address to Shareholders 13 Nov 2017 1:28PM $0.265 $0.027 fallen by 89.81%
- Quarterly Shareholder Update - September 2017 27 Oct 2017 8:58AM $0.270 $0.027 fallen by 90%
- Appendix 4C - quarterly 27 Oct 2017 8:58AM $0.270 $0.027 fallen by 90%
- Investor Presentation - 23 October 2017 23 Oct 2017 8:20AM $0.260 $0.027 fallen by 89.62%
- Pharmaxis Strengthens Drug Discovery Capability 19 Oct 2017 12:25PM $0.260 $0.027 fallen by 89.62%
- Copy of Corporate Governance Statement - 12 October 2017 12 Oct 2017 8:20AM $0.270 $0.027 fallen by 90%
- 2017 Appendix 4G - Key to Disclosures 12 Oct 2017 8:20AM $0.270 $0.027 fallen by 90%
- Notice of 2017 Annual General Meeting/Proxy Form 12 Oct 2017 8:20AM $0.270 $0.027 fallen by 90%
- 2017 Annual Report to Shareholders 12 Oct 2017 8:19AM $0.270 $0.027 fallen by 90%
- Appendix 3B - Exercise of employee options 9 Oct 2017 10:40AM $0.260 $0.027 fallen by 89.62%
- Investor Presentation 8 Sep 2017 8:51AM $0.270 $0.027 fallen by 90%
- Interview with CEO - New Phase 2 Study by Boehringer 8 Sep 2017 8:40AM $0.270 $0.027 fallen by 90%
- Boehringer Initiating Phase 2a Study Diabetic Retinopathy 8 Sep 2017 8:24AM $0.270 $0.027 fallen by 90%
- Antifibrotic LOXL2 Program Clears Preclinical Development 6 Sep 2017 8:37AM $0.270 $0.027 fallen by 90%
- Appendix 3B - Exercise of Employee Options 1 Sep 2017 2:12PM $0.265 $0.027 fallen by 89.81%
- Change in substantial holding 30 Aug 2017 9:46AM $0.265 $0.027 fallen by 89.81%
- Pharmaxis Investor Presentation 30 Aug 2017 9:35AM $0.265 $0.027 fallen by 89.81%
- Change in substantial holding 29 Aug 2017 5:39PM $0.265 $0.027 fallen by 89.81%

451 - 475 of 836 results

Page 19 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.